DEPARTMENT OF VETERANS AFFAIRS Justification and Approval (J&A) For Other Than Full and Open Competition (>SAT) Acquisition Plan Action ID: 36C245-27-AP-1021 Contracting Activity: Department of Veterans Affairs, VISN 05, NC05, Louis A Johnson VA Medical Center 1 Medical Center Drive Clarksburg, WV 26301 PR# 540-27-1-036-0349 Nature and/or Description of the Action Being Approved: The Louis A Johnson VA Medical Center Pharmacy IV room remains out of service due to ongoing flood remediation and displacement of essential compounding operations. This disruption has left our facility unable to compound hazardous medications needed for Oncology patients, placing timely access to prescribed treatments at risk. A new contract with an external provider to compound and ship these medications to the facility is essential to maintain continuity of care, prevent treatment delays, and sustain Oncology services in the interim of the compounding capabilities being restored. Due to the nature of services, there exists an unusual and compelling urgent need for this highly specialized service. The medical center requires the use of contractor due to the medical center s IV compounding room being down due to flood remediation, upgrades and recertification of the IV room and pharmacists/techs when re-opened. Existing contractual funding has been exhausted, and immediate contractual action is required to ensure continuity of these critical Oncology support services pending award of the follow-on procurement. The estimated value is $500,000.00. Description of Supplies/Services Required to Meet the Agency s Needs: The Clarksburg VA Medical Center requires emergency contract support to compound and ship hazardous medications for oncology patients. Flood remediation has displaced essential pharmacy operations and made the Pharmacy IV room unavailable, preventing on-site preparation. The contractor shall provide all chemotherapy agents, IV tubing, closed-system drug-transfer devices, and other necessary supplies. All hazardous chemotherapy agents shall be aseptically compounded according to patient-specific orders. The Medical Center can identify treatment needs including patient volume and treatment duration only one week in advance. Each week, the Clinical Pharmacy Practitioner will email the contractor a list of medications to be compounded and shipped to the Medical Center for patient treatment. Statutory Authority Permitting Other than Full and Open Competition: ( ) (1) Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements per 41 USC §3304(a)(1) as implemented by RFO 6.103-1; (X ) (2) Unusual and Compelling Urgency per 41 USC §3304(a)(2) as implemented by RFO 6.103-2; ( ) (3) Industrial Mobilization, Engineering, Developmental or Research Capability or Expert Services per 41 USC §3304(a)(3) as implemented by RFO 6.103-3; ( ) (4) International Agreement per 41 USC §3304(a)(4) as implemented by RFO 6.103-4 ( ) (5) Authorized or Required by Statute per 41 USC §3304(a)(5) as implemented by RFO 6.103-5; ( ) (6) National Security per 41 USC §3304(a)(6) as implemented by RFO 6.103-6; ( ) (7) Public Interest per 41 USC §3304(a)(7) as implemented by RFO 6.103-7; Demonstration that the Contractor s Unique Qualifications or Nature of the Acquisition Requires the Use of the Authority Cited Above (applicability of authority): Optum Infusion Services 308 LLC (Optum), is the only one source that is reasonably available because of urgency and who has agreed to continue to provide this highly specialized (hazardous drug compounding) supplies/services for our Oncology patients to ensure there are no unacceptable delays in patient care. Optum maintains sterile compounding operations compliant with applicable regulatory standards, including USP 797 and USP 800, and is capable of providing patient-specific hazardous chemotherapy compounding consistent with the Statement of Work applicable to Louis A Johnson VA Medical Center. Hazardous oncology treatments are clinically time-sensitive, and a transition to an alternate provider would require onboarding and validation activities that may pose a risk of service interruption. Description of Efforts Made to ensure that offers are solicited from as many potential sources as possible (including whether a notice was or will be publicized as required by RFO Part 5 and, if not, which exception under RFO Part 5 applies): In accordance with FAR 5.202(a)(2) The proposed contract action is made under the conditions described in 6.302-2 (or, for purchases conducted using simplified acquisition procedures, if unusual and compelling urgency precludes competition to the maximum extent practicable) and the Government would be seriously injured if the agency complies with the time periods specified in 5.203. The continuing loss of in-house compounding capability creates an immediate requirement for an external provider to prepare and deliver prescribed hazardous medications within clinically required treatment timelines. Failure to establish this support as soon as possible would place oncology treatments at risk of interruption or delay. Due to flood remediation and the resulting loss of in-house hazardous-drug compounding capability, the facility requires immediate external compounding and delivery support to prevent interruption of scheduled Oncology treatments. Delays associated with conducting a full and open competitive acquisition would risk interruption of patient care and adversely affect the Medical Center's ability to provide medically necessary chemotherapy treatments. The Government determined that continuation of services through Optum represents the most immediate and least disruptive means of maintaining continuity of care while acquisition actions for the follow-on requirement are completed. This limited-source approach is based on the unusual and compelling urgency of the requirement rather than a determination that no other provider is capable of performing the services. Market research will continue throughout performance to identify additional qualified sources capable of meeting future requirements. The results of this market research will be documented in the contract file and considered in the acquisition strategy for subsequent procurements. Determination by the CO that the Anticipated Cost to the Government will be Fair and Reasonable: The Independent Government Cost Estimate (IGCE) submitted with the acquisition package represents the Government s best estimate of anticipated costs for hazardous-drug compounding and delivery services. However, the specific chemotherapy medications, dosages, preparation quantities, and treatment frequencies will vary according to individual patients prescribed treatment regimens and clinical needs. Consequently, the exact mix and volume of services cannot be predicted with certainty before contract performance. The final price-reasonableness determination will be based on the pricing established for the services to be provided, rather than an assumption that actual patient utilization will precisely match the estimated quantities. The basis for that determination, including the limitations associated with patient-specific treatment requirements, will be documented in the contract file. Description of the Market Research Conducted and the Results, or a Statement of the Reasons Market Research Was Not Conducted: As described in Section 6 above, market research, in accordance with RFO Part 10, was conducted by synopsis of the proposed acquisition, advising industry of the pending acquisition and soliciting inquiries from interested parties. Any Other Facts Supporting the Use of Other than Full and Open Competition: Optum is currently providing hazardous chemotherapy compounding services to Clarksburg VAMC under IDIQ 36C24526D0059. This existing performance reflects established coordination with the facility and compliance with site-specific requirements. Listing of Sources that Expressed, in Writing, an Interest in the Acquisition: Optum Infusion Services 308 LLC was the only contractor that expressed interest in the acquisition and was available to continue performance within the timeframe necessary to prevent interruption of Oncology treatment services. Given the urgent requirement resulting from the continued outage of the Medical Center's Pharmacy IV room and the need for uninterrupted hazardous-drug compounding services, no other source was identified that could be implemented without transition-related delays that could adversely affect patient care. The Government will continue market research during performance to identify additional qualified sources for future requirements and to maximize competition to the extent practicable. A Statement of the Actions, if any, the Agency May Take to Remove or Overcome any Barriers to Competition before Making subsequent acquisitions for the supplies or services required: Ongoing market research will assess the availability and capabilities of additional providers, including eligible Service-Disabled Veteran-Owned Small Businesses and Veteran-Owned Small Businesses. The assessment will address each potential provider s ability to meet the required compounding, handling, shipping, delivery, and start-date requirements. Requirements Certification: I certify that the requirement outlined in this justification is a Bona Fide Need of the Department of Veterans Affairs and that the supporting data under my cognizance, which are included in the justification, are accurate and complete to the best of my knowledge and belief. Jason Boswell Administrative Officer Clarksburg VAMC 13. Approvals in accordance with the VHAPM Part 806.3 OFOC SOP: Contracting Officer Certification (required): I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. Mark Smith Contacting Officer NCO5